INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $631,956 | -9.2% | 12,132 | +10.3% | 0.04% | -5.4% |
| Q2 2023 | $696,330 | +14.1% | 10,997 | -2.4% | 0.04% | -2.6% |
| Q1 2023 | $610,162 | +40.6% | 11,268 | +37.4% | 0.04% | +35.7% |
| Q4 2022 | $434,103 | +20.9% | 8,203 | +6.4% | 0.03% | +7.7% |
| Q3 2022 | $359,000 | -18.6% | 7,711 | -0.2% | 0.03% | -7.1% |
| Q2 2022 | $441,000 | -4.3% | 7,724 | +2.5% | 0.03% | +47.4% |
| Q1 2022 | $461,000 | +25.3% | 7,534 | +7.0% | 0.02% | +58.3% |
| Q4 2021 | $368,000 | +46.0% | 7,040 | +4.2% | 0.01% | +50.0% |
| Q3 2021 | $252,000 | -15.4% | 6,757 | -7.7% | 0.01% | -20.0% |
| Q2 2021 | $298,000 | +31.3% | 7,321 | +9.6% | 0.01% | +11.1% |
| Q1 2021 | $227,000 | +64.5% | 6,679 | -44.7% | 0.01% | 0.0% |
| Q4 2018 | $138,000 | -57.3% | 12,084 | -18.8% | 0.01% | -25.0% |
| Q3 2018 | $323,000 | – | 14,879 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |